CA-JUNIPER-NETWORKS
18.7.2024 09:31:26 CEST | Business Wire | Press release
Telxius, a leading global connectivity provider, is scaling its core and edge network infrastructure to 400G with a Converged Optical Routing Architecture (CORA) provided by Juniper Networks (NYSE:JNPR), a leader in secure AI-Native Networks. This will enable a simplified network capacity expansion and efficient delivery of enhanced connectivity to metro networks and data center interconnects (DCI). It provides connectivity across distances of around 100 km to points of presence (PoPs) across Telxius’ global footprint in Spain, the Americas, and wider Europe.
Telxius connects millions of customers globally, providing a wide range of capacity, colocation and security services, as well as direct internet connectivity through its Tier-1 IP network. Its extensive ecosystem combines fiber optic submarine cables and terrestrial backhauls together spanning 100,000+ km, almost 100 PoPs in 17 countries, plus 27 data centers. Telxius seamlessly connects customers with ultra-high capacity, low latency and resilient networking.
Telxius will migrate some of its key architecture to Juniper’s CORA and PTX Series Packet Transport Routers to deliver a network that offers robust power and space savings superior performance and automated operations. This will free up a substantial amount of reserved bandwidth and allow for flexible extension to 400G capacity. The project will create enhanced connectivity for Telxius’ customers and create a more sustainable architecture by optimizing network scalability and bandwidth efficiency.
The solution leverages leading edge technology with the use of an IP over Dense Wavelength Division Multiplexing (IPoDWDM) solution. This maximizes routing platform capacity, scales up link bandwidth, and can reach more network locations and customers whilst removing the need to manage and maintain external DWDM equipment.
Using Juniper’s CORA, Telxius will simplify the network architecture by consolidating previously siloed IP and optical network layers into a unified system leveraging IPoDWDM. Once the project is complete, Telxius expects to increase network reliability for its customers, simplify network operations and substantially reduce power consumption.
“This project is a fantastic step forward to bring added scalability and capacity to the Telxius network through 400G coherent pluggable optics, meeting our customers’ needs in today’s ever-growing digital economy. Telxius is at the forefront of innovation, ensuring reduced power consumption and a simplified network architecture to provide a better experience for our customers. We anticipate a number of vendor-agnostic solutions that could support this architecture, and we are excited to collaborate with Juniper to build a solid foundation for further network expansion,” said Carlos Dasi, CTO, Telxius.
“400G optics are a highly reliable solution to further enhance Telxius’ infrastructure to enable the best experience for customers. Telxius is leading the way for network innovation with the deployment of Juniper’s PTX and CORA, and Juniper is proud to enable this network transformation. Juniper’s optics solutions provide a simplified integration with Juniper infrastructure that allows the customer to scale up and scale out their network in line with their business goals. Built to last, this network transformation will extend Telxius’ network longevity to future-proof the business,” said Julius Francis, Senior Director of Product Marketing, Juniper Networks.
About Telxius
As the world’s needs for uninterrupted global interconnectivity continue to rise, we are preparing the road ahead. Telxius is a leading global connectivity provider that combines subsea and terrestrial networks with data centers worldwide. Its extensive ecosystem includes eight next-generation fiber optic submarine cables and terrestrial backhauls together spanning 100,000+ km, almost 100 PoPs in 17 countries, plus 25 landing stations. Telxius provides a wide range of capacity, colocation and security services, as well as direct internet connectivity through its Tier-1 IP network. With ultra-high capacity, low latency and resilient networking, Telxius seamlessly connects customers across the Americas, Europe and beyond. For more information about Telxius visit www.telxius.com.
About Juniper Networks
Juniper Networks believes that connectivity is not the same as experiencing a great connection. Juniper's AI-Native Networking Platform is built from the ground up to leverage AI to deliver exceptional, highly secure and sustainable user experiences from the edge to the data center and cloud. Additional information can be found at Juniper Networks (www.juniper.net) or connect with Juniper on X (Twitter), LinkedIn, and Facebook.
Juniper Networks, the Juniper Networks logo, Juniper, Junos, and other trademarks listed here are registered trademarks of Juniper Networks, Inc. and/or its affiliates in the United States and other countries. Other names may be trademarks of their respective owners.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240718748438/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
